InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (14 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
14
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the detailed record of transactions filed by Kakkis Emil d, Chief Executive Officer. Director active across 1 company, notably Ultragenyx Pharmaceutical Inc.. In total, 24 filings have been recorded. Breakdown: 0 buy · 14 sells. Total volume traded: €8.5m. Activity tracked since 3 May 2021. The latest transaction was filed on 16 April 2026 (Attribution). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Kakkis Emil d
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations24 total
76,745 shares0Common StockSEC:0001193125-26-164308:0
71,177 shares0Common StockSEC:0001193125-26-089278:0
43,268 shares0Common StockSEC:0000950170-25-032779:0
11,727 shares@ US$42.233.8% of flowCommon StockSEC:0000950170-24-141485:0
20,000 shares0Common StockSEC:0000950170-24-135521:0
20,000 shares@ US$55.858.1% of flowCommon StockSEC:0000950170-24-103811:0
20,000 shares@ US$50.177.4% of flowCommon StockSEC:0000950170-24-092608:0
38,428 shares0Common StockSEC:0000950170-24-026625:0
30,000 shares@ US$45.0010.1% of flowCommon StockSEC:0001209191-24-002989:0
30,000 shares@ US$47.8710.4% of flowCommon StockSEC:0001209191-24-000071:0
47,853 shares@ US$6.862.5% of flowCommon StockSEC:0001209191-23-053351:0
8,716 shares0Common StockSEC:0001209191-23-016041:0
19,582 shares@ US$45.576.7% of flowCommon StockSEC:0001209191-23-000276:0
12,162 shares@ US$67.370.030% mcap11.5% of flowCommon StockSEC:0001209191-22-015799:0
853 shares@ US$81.000.6% of flowCommon StockSEC:0001209191-21-060749:0
852 shares@ US$115.710.8% of flowCommon StockSEC:0001209191-21-031383:0
30,000 shares@ US$107.8027.8% of flowCommon StockSEC:0001209191-21-030211:0
2,837 sharesCommon StockSEC:0001562180-16-001158:0
5,465 sharesCommon StockSEC:0001562180-16-001158:1
3,600 sharesCommon StockSEC:0001562180-16-001158:2
2,600 sharesCommon StockSEC:0001562180-16-001158:3
2,191 sharesCommon StockSEC:0001562180-16-001158:4
2,702 sharesCommon StockSEC:0001562180-16-001158:5
605 sharesCommon StockSEC:0001562180-16-001158:6
24 of 24 declarations
About Kakkis Emil d
KAKKIS EMIL D is President and CEO at Ultragenyx Pharmaceutical Inc. He has 24 filings in total, and across the sampled recent filings, sells total 8474976 EUR, with a date range from 2016-01-04 to 2026-04-20.
